CytoDyn Inc (NASDAQ:CYDY) announced its earnings results on Tuesday. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03), Bloomberg Earnings reports.

Shares of CytoDyn (NASDAQ:CYDY) opened at 0.673 on Wednesday. The stock’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.65. The firm’s market cap is $102.81 million. CytoDyn has a 12-month low of $0.46 and a 12-month high of $0.84.

CYDY has been the topic of a number of analyst reports. HC Wainwright set a $2.00 target price on CytoDyn and gave the company a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded CytoDyn from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine upgraded CytoDyn from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/11/cytodyn-inc-cydy-announces-earnings-results.html.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Receive News & Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related companies with MarketBeat.com's FREE daily email newsletter.